Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions
Neoplasms
Interventions
DRUG

Docetaxel

Docetaxel will be administered.

DRUG

Feladilimab

Feladilimab will be administered.

DRUG

Ipilimumab

Ipilimumab will be administered.

DRUG

GSK4428859A

GSK4428859A/EOS884448 will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

DRUG

GSK6097608

GSK6097608 will be administered.

Trial Locations (57)

10043

GSK Investigational Site, Orbassano to

10408

GSK Investigational Site, Gyeonggi-do

13620

GSK Investigational Site, Seongnam-si Gyeonggi-do

14033

GSK Investigational Site, Caen

14165

GSK Investigational Site, Berlin

20133

GSK Investigational Site, Milan

22927

GSK Investigational Site, Großhansdorf

28027

GSK Investigational Site, Madrid

28033

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28374

GSK Investigational Site, Pinehurst

28644

GSK Investigational Site, Cheongju Chungcheongbuk-do

29010

GSK Investigational Site, Málaga

33076

GSK Investigational Site, Bordeaux

34125

GSK Investigational Site, Kassel

34376

GSK Investigational Site, Immenhausen

37203

GSK Investigational Site, Nashville

37404

GSK Investigational Site, Chattanooga

39008

GSK Investigational Site, Santander

41009

GSK Investigational Site, Seville

44093

GSK Investigational Site, Saint-Herblain

47014

GSK Investigational Site, Meldola FC

48121

GSK Investigational Site, Ravenna

53100

GSK Investigational Site, Siena

69126

GSK Investigational Site, Heidelberg

75018

GSK Investigational Site, Paris

75230

GSK Investigational Site, Dallas

75248

GSK Investigational Site, Paris

80131

GSK Investigational Site, Napoli

82131

GSK Investigational Site, Gauting

90025

GSK Investigational Site, Los Angeles

94805

GSK Investigational Site, Villejuif

194291

GSK Investigational Site, Saint Petersburg

197183

GSK Investigational Site, Saint Petersburg

200347

GSK Investigational Site, Craiova

300166

GSK Investigational Site, Timișoara

407280

GSK Investigational Site, Floreşti

454048

GSK Investigational Site, Chelyabinsk

63110-1093

GSK Investigational Site, St Louis

10461-2375

GSK Investigational Site, The Bronx

T6G 1Z2

GSK Investigational Site, Edmonton

L6R 3J7

GSK Investigational Site, Brampton

M5G 2M9

GSK Investigational Site, Toronto

04357

GSK Investigational Site, Leipzig

1081 HV

GSK Investigational Site, Amsterdam

6229 HX

GSK Investigational Site, Maastricht

93-513

GSK Investigational Site, Lodz

60-569

GSK Investigational Site, Poznan

02-781

GSK Investigational Site, Warsaw

020142

GSK Investigational Site, Bucharest

075100

GSK Investigational Site, Otopeni

05505

GSK Investigational Site, Seoul

06080

GSK Investigational Site, Badajoz

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

SE-171 64

GSK Investigational Site, Stockholm

SE- 75 185

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

iTeos Belgium SA

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY